article thumbnail

FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial

Cannabis Law Report

Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the “ Company ” or “ FSD ”) announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide (“PEA”), or FSD-201, for use in treating COVID-19. TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. Anthony Durkacz. 1-844-978-3540.

article thumbnail

Flora Growth Forms Flora Pharma Division, Launches Global Clinical Trials

Cannabis Law Report

(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally. This document contains forward-looking statements. Visit www.floragrowth.ca

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Survey: Three Of Four Military Veterans Would Consider Using Medical Cannabis

NORML

Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). The organization represents over 400,000 veterans nationwide.

article thumbnail

Psilocybin-Alcohol Study, FDA’s Psychedelic Guide, & the NCAA’s Cannabis Overhaul Begins

Veriheal

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

article thumbnail

CBG ‘very helpful’ when treating medical conditions, first survey of its kind finds

The Cannigma

No clinical trial was used in the compilation of the study. The researchers themselves wrote that the study is the first “to document self-reported efficacy of CBG-predominant products,” and provides further indication that “CBG-predominant cannabis-based medicines should be studied in randomized controlled trials.”.

article thumbnail

Article: Intellectual Property Due Diligence in Psychedelics

Cannabis Law Report

For example, compounds such as psilocybin, mescaline, ibogaine, and LSD are being evaluated in clinical trials, but the compounds themselves are unpatentable because their existence is well documented in the prior art. However, that does not mean that the path to patents is closed off.

article thumbnail

Position: European Regulatory Lead – Remote MAPS PBC California Remote

Cannabis Law Report

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.